# CGBio's NOVO Factory receives construction approval in Hwaseong, South Korea

CGBio announced that its second plant, the NOVO Factory in Hyangnam, Hwaseong, Gyeonggi Province, received construction approval and has begun operations. The facility will manufacture NOVOSIS PUTTY and orthopedic surgery products for the U.S. and Japanese markets.

- Type: New facility
- Announced: 2026-03-04
- Where: Hyangnam, Hwaseong, Gyeonggi Province, South Korea
- Starts operating: 4 Mar 2026
- Status: completed
- Capacity: 1 million syringes per year (based on Novosis Putty 3mg specification)
- Products: NOVOSIS PUTTY, NOVOSIS OS (bone substitutes)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [CGBIO](https://endata.com/companies/42255.md)

## Sources

- [asiae.co.kr](https://www.asiae.co.kr/en/article/2026030409542417422), 2026-03-04: "With the completion of the facility, the company has secured a strategic production base to accelerate its entry into advanced markets such as the United States and Japan."
- [en.sedaily.com](https://en.sedaily.com/culture/2026/03/04/cgbio-launches-novo-factory-targeting-us-japan-markets), 2026-03-04: "Novo Factory has production capacity of up to 1 million syringes annually based on the Novosis Putty 3mg specification."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.